1167 related articles for article (PubMed ID: 25733317)
1. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
2. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
Sargento L; Satendra M; Longo S; Lousada N; Palma dos Reis R
Clin Cardiol; 2013 Nov; 36(11):677-82. PubMed ID: 23929789
[TBL] [Abstract][Full Text] [Related]
3. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study).
Schou M; Gustafsson F; Videbaek L; Andersen H; Toft J; Nyvad O; Ryde H; Fog L; Jensen JC; Nielsen OW; Lind-Rasmussen S; Abdulla J; Hildebrandt PR;
Eur J Heart Fail; 2013 Jul; 15(7):818-27. PubMed ID: 23507787
[TBL] [Abstract][Full Text] [Related]
4. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
6. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
8. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
9. Old markers, new approach to assessment of risk in heart failure.
Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
[TBL] [Abstract][Full Text] [Related]
10. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
11. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
[TBL] [Abstract][Full Text] [Related]
12. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
13. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
[TBL] [Abstract][Full Text] [Related]
15. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
16. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
[TBL] [Abstract][Full Text] [Related]
18. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
20. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
